Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma. 
Cervical metastases from unknown primary tumors are rare and no clear therapeutic options are available.  This retrospective analysis aimed to evaluate toxicity and activity of a sequential chemoradiation regimen consisting of induction chemotherapy followed by extended-field radiotherapy in patients with cervical metastases from unknown primary tumors.  Patients with cytological or histological diagnosis of latero-cervical lymph-node metastasis from carcinoma with unknown origin treated with sequential chemotherapy (3 cycles of docetaxel and cisplatin, each administered as intravenous infusion at the dose of 75 mg/m(2) on day 1, every 21 days) and radiotherapy (cumulative dose of 70 Gy) were included in this study.  The radiological response was assessed by central review according to the revised RECIST criteria.  Fifteen patients received three cycles of induction chemotherapy with the combination of docetaxel and cisplatin.  Patients were subsequently treated with extended-field radiotherapy.  Three complete responses were observed after induction chemotherapy and 13 after the chemoradiation treatment.  The overall response rate after chemoradiation, was 93.3% (14 of 15 evaluable patients).  One year disease-free-survival was 83.3% (10 of 12 evaluable patients).  Treatment was well-tolerated; two cases of grade 4 neutropenia, two of grade 3 mucositis and eight of grade 2 nausea were the worst, most clinically-relevant side-effects.  Induction chemotherapy followed by extended-field radiotherapy showed good activity and manageable toxicity in patients with cervical metastases from unknown primary tumors.